Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Elinder Camburn

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Pathology|July 3, 2019
Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypesAnna Elinder Camburn, Michelle Petrasich, Anna Ruskova, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2022
Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell TransplantMay Chiu, Samuel Hague, Anna Elinder-Camburn, et al.
Journal of Geriatric Oncology|December 15, 2021
Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphomaJesse Zhang, Patricia Disperati, Anna Elinder-Camburn, et al.
Infection Control and Hospital Epidemiology|December 11, 2012
Central line-associated bloodstream infections in adult hematology patients with febrile neutropenia: an evaluation of surveillance definitions using differential time to blood culture positivityJoshua T Freeman, Anna Elinder-Camburn, Catherine McClymont, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2023
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic LeukemiaJohn N Allan, Ian W Flinn, Tanya Siddiqi, et al.
Lancet (London, England)|December 10, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trialLorenzo Falchi, Marcel Nijland, Huiqiang Huang, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Pathology|July 3, 2019
Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypesAnna Elinder Camburn, Michelle Petrasich, Anna Ruskova, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2022
Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell TransplantMay Chiu, Samuel Hague, Anna Elinder-Camburn, et al.
Journal of Geriatric Oncology|December 15, 2021
Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphomaJesse Zhang, Patricia Disperati, Anna Elinder-Camburn, et al.
Infection Control and Hospital Epidemiology|December 11, 2012
Central line-associated bloodstream infections in adult hematology patients with febrile neutropenia: an evaluation of surveillance definitions using differential time to blood culture positivityJoshua T Freeman, Anna Elinder-Camburn, Catherine McClymont, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2023
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic LeukemiaJohn N Allan, Ian W Flinn, Tanya Siddiqi, et al.
Lancet (London, England)|December 10, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trialLorenzo Falchi, Marcel Nijland, Huiqiang Huang, et al.
Pageof 1